Connor, Clark & Lunn Investment Management (CC&L)
CADX

Connor, Clark & Lunn Investment Management (CC&L)’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-32,119
Closed -$309K – 844
2013
Q4 		$309K Buy
+32,119
New +$232K ﹤0.01% 594

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CADX Position: Q1 2014 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 32,119 shares — an estimated $309K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CADX in Q4 2013 and held it in 1 quarter. The position peaked at $309K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 32,119 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $309K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q4 2013 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s CADENCE PHARMACEUTICALS, INC COM STK position peaked at $309K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2014, filed 14 May 2014.